XML 83 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACQUISITIONS AND LICENSING AGREEMENTS - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 29, 2023
USD ($)
rate
Jul. 06, 2023
USD ($)
Jan. 17, 2023
USD ($)
Jan. 31, 2025
USD ($)
therapy
Dec. 31, 2024
USD ($)
Jan. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jul. 19, 2024
USD ($)
Dec. 12, 2022
USD ($)
Asset Acquisition And Business Combination [Line Items]                        
Current portion of contingent consideration liability         $ 49,000,000   $ 39,000,000 $ 49,000,000 $ 39,000,000      
Goodwill         11,087,000,000   11,183,000,000 11,087,000,000 11,183,000,000 $ 11,547,000,000    
Other expense, net               247,000,000 28,000,000 35,000,000    
Interest expense, net               1,388,000,000 1,328,000,000 $ 1,464,000,000    
Trade receivables, net         2,140,000,000   1,998,000,000 2,140,000,000 1,998,000,000      
Inventories, net         1,595,000,000   1,544,000,000 1,595,000,000 1,544,000,000      
Property, plant and equipment, net         1,780,000,000   1,707,000,000 1,780,000,000 1,707,000,000      
Intangible assets, net         5,551,000,000   6,456,000,000 5,551,000,000 6,456,000,000      
Deferred tax liabilities, net         128,000,000   163,000,000 128,000,000 163,000,000      
Bausch + Lomb | Paragon Bio Teck Inc. Asset Acquisition and Total Titanium Inc. Business Combination                        
Asset Acquisition And Business Combination [Line Items]                        
Goodwill                       $ 5,000,000
Trade receivables, net                       1,000,000
Inventories, net                       1,000,000
Property, plant and equipment, net                       2,000,000
Intangible assets, net                       43,000,000
Deferred tax liabilities, net                       $ 11,000,000
Bausch + Lomb | Johnson & Johnson Vision, Blink Product Line Acquisition                        
Asset Acquisition And Business Combination [Line Items]                        
Cash consideration paid, asset acquisition   $ 107,000,000                    
Elios Vision | Bausch + Lomb                        
Asset Acquisition And Business Combination [Line Items]                        
Cash consideration paid         99,000,000              
Consideration transferred         188,000,000              
Contingent consideration, liability         89,000,000     89,000,000        
Aggregate purchase consideration         188,000,000     188,000,000        
Intangible assets, net         177,000,000     177,000,000        
Goodwill         27,000,000     27,000,000        
Other non-current assets         1,000,000     1,000,000        
Trukera Medical | Bausch + Lomb                        
Asset Acquisition And Business Combination [Line Items]                        
Aggregate purchase consideration                     $ 24,000,000  
Intangible assets, net                     16,000,000  
Other net assets                     6,000,000  
Goodwill                     $ 2,000,000  
XIIDRA® and Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb                        
Asset Acquisition And Business Combination [Line Items]                        
Cash consideration paid $ 1,750,000,000                      
Consideration transferred 1,753,000,000                      
Potential future regulatory approval milestone obligations, lower range 750,000,000                      
Contingent consideration, liability 3,000,000                      
Aggregate purchase consideration 1,753,000,000                      
Intangible assets, net 1,600,000,000                      
Goodwill $ 23,000,000                      
Measurement period adjustment, prepaid expenses and other current assets             5,000,000          
Measurement period adjustment, intangible assets, net             5,000,000          
Inventory release turnover cycle, favorable contract, term 2 years                      
Inventory released to cost of goods sold               81,000,000 20,000,000      
Revenues since acquisition             106,000,000          
Earnings since acquisition             $ 17,000,000          
XIIDRA® and Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Acquisition-Related Transaction Costs                        
Asset Acquisition And Business Combination [Line Items]                        
Other expense, net                 20,000,000      
XIIDRA® and Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Acquisition-Related Finance Costs                        
Asset Acquisition And Business Combination [Line Items]                        
Interest expense, net                 $ 16,000,000      
XIIDRA® and Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Cash Payable Upon the Achievement of Specified Commercialization and Sales Milestones for Certain Pipeline Products                        
Asset Acquisition And Business Combination [Line Items]                        
Potential future regulatory approval milestone obligations, lower range $ 475,000,000                      
XIIDRA® and Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Cash Payable Upon the Achievement of Specified Sales Milestones                        
Asset Acquisition And Business Combination [Line Items]                        
Potential future regulatory approval milestone obligations, lower range 275,000,000                      
XIIDRA® and Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Milestone Payments                        
Asset Acquisition And Business Combination [Line Items]                        
Contingent consideration, liability $ 31,000,000                      
XIIDRA® and Certain Other Ophthalmology Assets Acquisition | Bausch + Lomb | Milestone Payments | Measurement Input, Discount Rate                        
Asset Acquisition And Business Combination [Line Items]                        
Fair value, contingent consideration obligations, discount rate | rate 0.11                      
AcuFocus, Inc. Acquisition | Bausch + Lomb                        
Asset Acquisition And Business Combination [Line Items]                        
Cash consideration paid           $ 31,000,000            
Consideration transferred     $ 35,000,000                  
Contingent consideration, liability     5,000,000                  
Goodwill     $ 8,000,000                  
Purchase price, repayment term     18 months                  
Intangibles, net     $ 28,000,000                  
Other non-current assets     9,000,000                  
Liabilities     $ 6,000,000                  
Whitecap Biosciences Acquisition | Bausch + Lomb | Subsequent Event                        
Asset Acquisition And Business Combination [Line Items]                        
Cash consideration paid       $ 28,000,000                
Number of innovative therapies | therapy       2                
Elios Vision Acquisition | Bausch + Lomb                        
Asset Acquisition And Business Combination [Line Items]                        
Current portion of contingent consideration liability         11,000,000     11,000,000        
Elios Vision Acquisition | Bausch + Lomb | Cash Payable Upon the Achievement of Specified Sales Milestones                        
Asset Acquisition And Business Combination [Line Items]                        
Potential future regulatory approval milestone obligations, lower range         75,000,000     75,000,000        
Potential future regulatory approval milestone obligations, lower range         375,000,000     375,000,000        
Elios Vision Acquisition | Bausch + Lomb | Cash Payable Upon the Achievement of Specific Regulatory Approval Milestones                        
Asset Acquisition And Business Combination [Line Items]                        
Potential future regulatory approval milestone obligations, lower range         50,000,000     50,000,000        
Potential future regulatory approval milestone obligations, lower range         $ 145,000,000     $ 145,000,000